16:49 , Apr 25, 2019 |  BC Extra  |  Company News

Lilly pulling Lartruvo after failure in confirmatory study

Following the failure in January of Lartruvo olaratumab to show a survival benefit in a confirmatory study, Lilly now intends to withdraw the drug from the market. Since 2016, Lartruvo has been approved to treat...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
21:46 , Mar 29, 2019 |  BC Extra  |  Financial News

Blueprint raises $300M in follow-on, speeds regulatory timelines

Days after revealing new timelines for its lead program, Blueprint raised $300 million in a follow-on priced late Thursday. Blueprint Medicines Corp. (NASDAQ:BPMC) sold 4.1 million shares at $74, a 7% discount to the company's...
21:05 , Mar 15, 2019 |  BioCentury  |  Finance

HaiHe's listing recipe

While a recent mega-round raised by HaiHe could position the Shanghai-based company to go public this year, lead investor Huagai Capital is not looking for an exit at least until the company’s first products hit...
23:20 , Feb 13, 2019 |  BC Week In Review  |  Financial News

HaiHe raises $147M in series B to advance cancer candidates

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) raised $146.6 million on Feb. 11 to advance its oncology focused pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical...
23:19 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13...
22:08 , Feb 11, 2019 |  BC Extra  |  Financial News

HaiHe raises $147M in series B to advance cancer candidates

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) raised $146.6 million to advance its oncology focused pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical Group Ltd., Hillhouse...
00:27 , Feb 8, 2019 |  BC Extra  |  Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...
18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
21:12 , Feb 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I diabetes....